AT A GLANCE

Key features of influenza, SARS-CoV-2 and Other Common Respiratory Viruses

9/30/2020

Introduction

This document provides a high-level overview of the key features of:

- influenza
- SARS-CoV-2 (the virus that causes COVID-19)
- respiratory syncytial virus (RSV)
- rhinovirus

that may circulate over the course of the respiratory virus season (fall to early spring). Signs and symptoms of illness caused by these respiratory viruses can be very similar and therefore cannot be diagnosed without laboratory testing. These four viruses, along with other viruses, can cause outbreaks in facilities during the respiratory virus season. In some outbreaks, more than one virus may be identified, while in other outbreaks a causative virus may not be identified despite testing.

Due to the evolving nature of the COVID-19 situation, information presented in this document related to SARS-CoV-2 reflects what is known at the time of publication.
# Table 1: Comparison of key features of influenza, SARS-CoV-2, respiratory syncytial virus (RSV) and rhinovirus

<table>
<thead>
<tr>
<th>Key features</th>
<th>Seasonal Influenza</th>
<th>SARS-CoV-2 (COVID-19)</th>
<th>Respiratory Syncytial Virus (RSV)</th>
<th>Rhinovirus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most common symptoms</td>
<td>Sudden onset of fever, cough, chills, headache, fatigue, sore throat, runny or stuffy nose, muscle pain or body aches&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Similar to influenza with the possibility of other symptoms, including loss of taste and smell&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Similar to influenza&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Runny nose, sneezing, cough, sore throat, muscle pain, fatigue, no or mild fever&lt;sup&gt;1,2&lt;/sup&gt;</td>
</tr>
<tr>
<td>More severe manifestation/complications</td>
<td>Pneumonia, worsening of underlying medical conditions, sepsis, cardiac involvement, neurologic involvement, death&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Pneumonia, sepsis, blood clots, cardiac involvement, neurologic involvement, renal involvement&lt;sup&gt;4&lt;/sup&gt;, multisystem inflammatory syndrome in children (MIS-C)&lt;sup&gt;5&lt;/sup&gt;, death&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Pneumonia, bronchiolitis, death&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Lower respiratory tract infection (pneumonia, bronchiolitis) in infants&lt;sup&gt;1&lt;/sup&gt;, bronchitis&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Risk groups for complications</td>
<td>Young children; older adults; underlying medical conditions, including immunocompromised; obesity; pregnancy&lt;sup&gt;2,6&lt;/sup&gt;</td>
<td>Older adults&lt;sup&gt;5,6&lt;/sup&gt;; underlying medical conditions, including immunocompromised&lt;sup&gt;5,6&lt;/sup&gt;; obesity&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Infants and children less than 2 years of age with congenital heart disease or chronic lung disease; premature infants; older adults; underlying medical conditions, including immunocompromised&lt;sup&gt;1,2&lt;/sup&gt;</td>
<td>Young children; immunocompromised; respiratory conditions&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Strains</td>
<td>Frequent mutations; different types, subtypes, strains&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Mutations but no major genetic changes to date&lt;sup&gt;7&lt;/sup&gt;</td>
<td>Subgroups and genotypes&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Many serotypes&lt;sup&gt;1,2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Key features</td>
<td>Seasonal Influenza</td>
<td>SARS-CoV-2 (COVID-19)</td>
<td>Respiratory Syncytial Virus (RSV)</td>
<td>Rhinovirus</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------</td>
<td>-----------------------</td>
<td>----------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Incubation period</strong></td>
<td>1 to 4 days⁸</td>
<td>1 to 14 days; median: 5 to 6 days⁵</td>
<td>3 to 7 days⁸</td>
<td>2 to 4 days⁸</td>
</tr>
<tr>
<td>Time period from exposure to onset of symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Communicable Period</strong></td>
<td>1 day before and until about 5-10 days after onset of symptoms (peaks 24-48 hours after symptom onset)¹, ⁸</td>
<td>Period of communicability is still uncertain but evidence suggests ~48 hours before to ~10 days after symptom onset;⁴ Some people with severe COVID-19 infection may be infectious for longer⁹</td>
<td>Usually until 3 to 8 days after symptom onset, but can sometimes be up to 4 weeks in infants and those who are immunocompromised¹</td>
<td>1 to 3 weeks (peaks 2-3 days after symptom onset)⁸</td>
</tr>
<tr>
<td>Time period when can be spread to others</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>How is the virus spread?</strong></td>
<td>Direct person-to-person transmission and fomites, and possibly small aerosols under certain conditions¹, ⁸</td>
<td>Predominately by direct person-to-person transmission, and possibly fomites⁴ or small aerosols under certain conditions¹², ¹³, ⁸</td>
<td>Direct person-to-person transmission and fomites¹</td>
<td>Direct person-to-person transmission and fomites¹</td>
</tr>
<tr>
<td><strong>Spread before symptoms start</strong></td>
<td>Yes, can spread from 24 hours before symptoms starts;⁴, ¹⁰</td>
<td>Yes, from ~ 48 hours or possibly earlier before symptom onset;⁴, ¹¹</td>
<td>Uncertain, has not been well studied</td>
<td>Uncertain, has not been well studied</td>
</tr>
<tr>
<td><strong>Spread while having no symptoms</strong></td>
<td>Infected people can have no symptoms and may spread the virus to others¹⁰</td>
<td>Possible to spread while asymptomatic¹¹</td>
<td>Uncertain, has not been well studied</td>
<td>Uncertain, has not been well studied</td>
</tr>
<tr>
<td>Key features</td>
<td>Seasonal Influenza</td>
<td>SARS-CoV-2 (COVID-19)</td>
<td>Respiratory Syncytial Virus (RSV)</td>
<td>Rhinovirus</td>
</tr>
<tr>
<td>------------------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>----------------------------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| **Type of precaution**       | Droplet and contact\(^{14}\) | Droplet and contact; 
Airborne when performing aerosol-generating medical procedures\(^{15}\) | Droplet and contact\(^{14}\) | Droplet and contact\(^{14}\) |
| **How infectious is the virus?** | \(R_0: 1.27^{*16}\) | \(R_0: 3.32^{*17}\) | \(R_0: 3.0^{*18}\) | Not available |
| **Case fatality**             | <0.1\(^{6}\)     | Variable ~ 3\(^{19}\) | Not available | Extremely unlikely to result in death\(^{2}\) |
| **Vaccine**                  | Seasonal vaccine available and recommended annually\(^{20}\) | Currently in development | Currently in development; 
Palivizumab, a humanized monoclonal immunoglobulin, available for prevention in some high risk infants\(^{3}\) | No vaccine |

Comparing Key Features of Influenza, SARS-CoV-2 and Other Common Respiratory Viruses  4
<table>
<thead>
<tr>
<th>Key features</th>
<th>Seasonal Influenza</th>
<th>SARS-CoV-2 (COVID-19)</th>
<th>Respiratory Syncytial Virus (RSV)</th>
<th>Rhinovirus</th>
</tr>
</thead>
</table>
| Antiviral medications| Used for treatment in those with moderate or severe illness or at risk for complications of influenza\(^{21}\)  
Recommended for both treatment and prevention in outbreaks in closed settings, especially if residents are at high risk of complications\(^{21}\) | Approved treatments (dexamethasone\(^{22}\), remdesivir\(^{23}\)) are available for hospitalized patients with particular indications;  
Trials for therapies are ongoing | None routinely recommended                                                                 | None      |

\(^{21}\) It is increasingly recognized that respiratory virus may be contained in particles of various sizes, including larger droplets and smaller aerosols (see Focus On: COVID-19: Aerosol Generation from Coughs and Sneezes\(^{12}\); COVID-19 Routes of Transmission-What We Know So Far\(^{13}\)).  

\(^{*}\) R\(_0\): Basic reproductive numbers - Average number of people who become infected by an infectious person when everyone is susceptible to the infection.
References


11. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 – What we know so far about...asymptomatic infection and asymptomatic transmission [Internet].


Citation

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

At a Glance
An At a Glance is a brief document offering an overview of a topic or steps in a process, in a concise manner.

Public Health Ontario
Public Health Ontario is an agency of the Government of Ontario, dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.